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The rational for allogeneic transplantation as therapy for
inherited metabolic disease was provided by the funda-
mentally important work done by Neufeld’s group over 40
years ago, conﬁrming that normal cells could “cross-correct”
cells with storage diseases such as Hurler syndrome. Initial
reports in the early 1980s conﬁrmed that these patients
could be transplanted, resulting in improvement in visceral
disease in patients with mucopolysaccharide accumulation.
Later investigations suggested that transplantation arrested
neurologic deterioration in some disorders, such as Hurler
syndrome (mucopolysaccharidosis type IH [MPS IH]), but is
less effective in achieving stabilization of cognitive function
in MPS II (Hunter) and MPS III (Sanﬁlippo). It is thought that
the engraftment of donor-derived microglia results in the
delivery of enzyme in the central nervous system, but the
reasons transplantation is more successful for MPS IH than
MPS II or MPS III remain elusive.
Transplantation was also tested as therapy for lysosomal
leukodystrophies, including Krabbe (globoid cell leukodys-
trophy, or GLD) and metachromatic leukodystrophy (MLD).
ALthough isolated reports of success in disease stabilization
for GLD and MLD exist, due to heterogeneity of disease
phenotypes and degree of disease advancement at the time
of transplantation, analysis of these outcomes are difﬁcult,
and there are no large multicenter reports of outcomes.
Reports of success in the use of transplantation for adreno-
leukodystrophy (ALD) were ﬁrst published in the 1990s.
Because ALD is a peroxisomal disorder, the biology by which
transplantation exerts its beneﬁcial effects is distinct from
that of GLD and MLD. Other rare inherited metabolic
diseases, including osteopetrosis, mannosidosis, Maroteaux-
Lamy syndrome (MPS VI), and Wolman disease, for instance,
have also been reported to respond to transplantation.
New developments have affected approaches to trans-
plantation for these disorders. The availability of enzyme
replacement therapy (ERT) has provided the opportunity to
explore combination therapy in disorders such as Hurler
syndrome, whereas in other diseases, such as Maroteaux-
Lamy syndrome, ERT has essentially replaced trans-
plantation as standard therapy. In addition, cord blood (CB)
transplantation has allowed patients to move to transplantFinancial disclosure: See Acknowledgments on page S62.
* Correspondence and reprint requests: Paul Orchard, MD, 660B Cancer
Center Research Building, MCC 366, 420 Delaware Street SE, Minneapolis,
MN 55455.
E-mail address: orcha001@umn.edu (P. Orchard).
1083-8791/$ e see front matter  2013 American Society for Blood and Marrow
http://dx.doi.org/10.1016/j.bbmt.2012.10.026of transplantation as an option for patients with rapidly
progressive disease, and possibly improving outcomes. In
addition, newborn screening is becoming available, or will be
on the horizon for diseases such asHurler, ALD, and especially
GLD, which may change the dynamics of transplantation.
However, although much has changed in the use of trans-
plantation for these disorders,much remains the same. These
are raredisorders, and few institutions see sufﬁcient numbers
of patients to provide meaningful reports of outcomes.
Although the possibility of prospective multi-institutional
studies could address these deﬁciencies, there is to date
little uniﬁcation in approaches to transplantation and in the
assessment of patients before or after transplant. The devel-
opment of infrastructure to standardize these parameters
would be extremely beneﬁcial in this regard. If we wish to
make continued progress in determining which patients will
best beneﬁt from transplantation, how best to proceed with
transplantation, and how to anticipate andminimize disease-
related complications later in life, it will be critical to develop
the means of performing these cooperative studies.
PREDICTORS OF OUTCOME OF HURLER SYNDROME
PATIENTS AFTER SUCCESSFUL HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Jaap Jan Boelens
Background: Transplantation for Hurler Syndrome
Hurler syndrome (HS) is themost severe phenotype in the
spectrum of MPS I, a type of lysosomal storage disorder.
Untreated HS patients develop progressive and ultimately
fatal multisystem deterioration, including psychomotor
retardation, severe skeletal manifestations, and life-
threatening cardiac and pulmonary complications due to
severe deﬁciency or complete absence of the lysosomal
enzyme a-L-iduronidase. Based on in vitro studies doc-
umenting cross-correction of cells from MPS patients with
normal cells [1], hematopoietic cell transplantation (HCT)was
introduced as a treatment for HS in the early 1980s [2]. After
HCT, engrafting donor hematopoietic cells serve as a perma-
nent source of cellular enzyme replacement in the tissues,
including the brain through engraftment of donor microglial
cells in the central nervous system. Intravenous ERT, available
for MPS I patients since 2003, does not prevent central
nervous system deterioration [3,4], and therefore allogeneic
HCT remains the standard of care for patients with HS.
Worldwide, based on the European Group for Blood and
Marrow Transplantation (EBMT) and Center for InternationalTransplantation.
Table 1
Suggested Donor Hierarchy and Conditioning
Stem cell source hierarchy in lysosomal storage diseases:
1. Identical siblings (not carriers)
2. UD (10/10) ¼ UCB (6/6)
3. UCB (5/6)
4. UCB (4/6) ¼ mismatched UD (non-T depleted)
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over 500 HCTs have been performed in HS patients, making
HS the most frequently transplanted inherited metabolic
disease. Historically, HCT for Hurler syndromewas limited by
donor availability, graft failure or mixed chimerism, and high
transplantation-related morbidity and mortality [5].
Although more recently outcomes have improved, with
improved survival and stabilization of issues such as cardiac
and cognitive function, residual disease burden remains
present. Due to the unique characteristics of this disease, it is
critical to assess transplant-related outcomes speciﬁcally in
this population. This includes issues such as which patients
are appropriate for transplantation, choice of conditioning
regimens, and choice of donor. To address these questions, it
is of utmost importance to develop collaborative, interna-
tional studies to identify predictors of outcomes in HS.Results of Multi-Institutional Studies
To identify predictors for graft failure and HCT-associated
toxicity, various studies were performed. In a European
retrospective study (n¼146), bothTcell depletionand theuse
of a reduced-intensity conditioning regimenwere found to be
associated with graft failure, whereas targeted busulfan pro-
tected against graft failure. Interestingly, studies using unre-
lated cord blood (UCB) as a stem cell source for HCT for HS (as
well as in other inherited metabolic diseases) showed high
rates of full donor chimerism associatedwith normal enzyme
levels after engraftment [6-8]. Because full donor chimerism
associated with normal enzyme levels are thought to be
associated with superior long-term outcomes, including
neurocognitive outcome after HCT, CB has been used as
a viable alternative option, or even as a preferential stem cell
source, for HS patients [9]. A worldwide cell source study of
patients reported to the EBMT, Eurocord, and the CIBMTR
supports transplantation early (preferably age < 16 months)
and with the best human leukocyte antigenematched donor
[10]. In this analyses, of 258 HS patients receiving myeloa-
blative conditioning, the 5-year event-free survival rate with
a matched sibling donor or 6/6 matched UCB were similar at
81%, whereas in recipients of a 10/10 human leukocyte anti-
genematched unrelated donor (UD) graft itwas 66% andwith
the use of a 5/6 matched CB it was 68%. Predictors for lower
event-free survival rates were HCT using a 4/6 matched UCB
unit (57%; P ¼ .031), human leukocyte antigenemismatched
UD (41%; P ¼ .004), and T cell depleted UD (36%; P ¼ .005).
Consistent with previous reports, this study showed that in
surviving patients CB recipients had increased full-donor
chimerism (92%; P ¼ .007) and normal enzyme levels (98%;
P¼ .039) compared with the other grafts sources and donors.
A possible explanation for this could be the increased pluri-
potential capability of the CB stem cell relative to the adult
bone marrow or peripheral blood stem cell, with higher
proliferative potentials [11,12]. Another could be the more
recent use of targeted intravenous busulfan.Disease-Related Outcomes after Transplantation
Despite these areas of success, some disease manifesta-
tions of HS persist and even progress after HCT. Of note,
musculoskeletal features often require orthopedic surgical
interventions [13,14]. Additionally,manyconditionspresent at
diagnosis or HCT may be irreversible, including neuro-
cognitive dysfunction and corneal clouding [13]. Overall, the
long-term clinical outcome for HS children receiving HCT
appears to be promising, but it varies from child to child. This
variability is presumably due to genotype, age and clinical
status at HCT, enzyme activity level achieved after transplant,
donor chimerism status, and stem cell source [13]. Because
detailed long-term follow-up data are difﬁcult to obtain, an
international multicenter study was initiated to assess the
long-term outcome of successfully transplanted HS patients
and predictors of disease-related complications (MPS
Symposium 2012, Noordwijkerhout, the Netherlands). HS
patients transplanted between 1980 and 2007 within the
leading transplantation centers in Europe and the United
States were included. Patient, donor, and transplantation-
related variables that may inﬂuence long-term outcome
were analyzed in regards to various organ systems, including
orthopedic, cardiac, ophthalmologic, respiratory, and audio-
logic. In this study of 197 surviving HS patients (estimated to
be 70% to 80% of the successfully transplanted HS patients
through 2007) were included. The median follow-up was 88
months (range, 36 to 258). These studies showed that normal
enzyme levels were associated with fewer surgical interven-
tions, for example, cord compression (hazard ratio .081, P ¼
.021) or genu valgum surgery (hazard ratio .352, P ¼ .013).
Genotype (double nonsense versus any other genotype) was
associated with a lower probability of having surgery for hip
dysplasia (hazard ratio .251, P ¼ .007). In addition, lower
enzyme levels after transplantation were associated with
increased complications related to cardiac ﬁndings (progres-
sion of valvular insufﬁciency), ophthalmologic changes
(increased corneal clouding), and audiologic outcomes (the
requirement for hearing aids). In contrast, younger age at HCT
was associated with better outcomes. Furthermore, as might
be expected, the outcomes of HCTare optimal if the transplant
occurs before neurologic symptoms appear. Thus, the long-
term outcome of clinical manifestations in HS patients after
successful HCT is promising, although residual disease burden
remains. Predictors inﬂuencing the long-term outcomes are
enzyme level after HCT, genotype, and age at HCT.
Future Challenges in the Treatment of HS
Small numbers of patients, limited structure for interna-
tional collaborations, and the lack of universal guidelines for
assessments are often limitations for studies in rare diseases.
These factors slow progress in accumulating the critical data
necessary to improving and implementing novel therapies.
To achieve further improvement of outcomes in HS and other
rare, devastating disorders, we as a transplant community
need to standardize and centralize therapy and outcome
measures for these rare diseases. This requires the develop-
ment of an infrastructure that supports the development of
an “international network.” These collaborative efforts will
allow us to further reﬁne the treatment of patients with HS
and other inherited metabolic diseases. With continued
reﬁnement, cellular therapy may be offered to more patients
in a safer and more effective manner.
The most recent data obtained from international collab-
orative studies supports referral for HCT early in life by using
the best-matched cell source. CB seems particularly attractive
P. Orchard et al. / Biol Blood Marrow Transplant 19 (2013) S58eS63S60for transplantation in HS because these units are readily
available, and data suggest a high likelihood of achieving full
donor chimerism associated with normal enzyme levels
when a myeloablative preparative regimen is used. On this
basis, a means of choosing the graft for these patients is pre-
sented in Table 1. It is important to recognize that most
matched sibling donors are carriers, leading to lower enzyme
levels, even if full donor chimerism is achieved. Therefore,
evenwhen amatched sibling donor is available, the risks and
beneﬁts of transplantation with a graft from a heterozygous
related donor should be considered in regards to long-term
control of disease-related complications. The prospect
of newborn screening facilitating early HCT, the use of
noncarrier donors, and the potential to achieve full-donor
chimerism while minimizing toxicity will prove crucial in
optimizing long-term outcomes. International collaboration
and network building is of utmost importance to gather data




Clinical Manifestations of Adrenoleukodystrophy
ALD was described in 1923 by Siemerling and Creutzfeldt
as a condition characterized by hyperpigmentation and
central nervous system demyelination. In 1976 Igarashi and
colleagues observed that saturated very-long-chain fatty
acids (VLCFAs) accumulate in the brain and adrenal tissue of
patients with ALD [15]. The impaired capacity to degrade
VLCFA in patients with ALD has been shown to be due to
mutations in a gene encoding a peroxisomal membrane
protein, now designated ABCD1. The condition is X-linked in
inheritance, with an incidence of approximately 1 in 17,000,
and seems tobe similar in distribution across ethnic and racial
groups [16]. Importantly, within speciﬁc kindred substantial
clinical variability exists despite a single genotype. In the
pediatric population (up to age 20), approximately 50% of
boys develop adrenal insufﬁciency, whereas in 35% to 40% an
acute, inﬂammatory, demyelinating condition develops,
termed cerebral ALD (C-ALD) [17]. In others, generally in the
third or fourth decade of life, an axonal process develops in
the spinal cord long tracts, termed adrenomyeloneuropathy.
This is considered the “adult form” of the disease, generally
associatedwith a slowdeteriorationofmotor functionbut not
necessarily central white matter changes.
Allogeneic Stem Cell Transplantation for C-ALD
Themedian age at development of C-ALD is 7 years old. To
date, no factors have been identiﬁed that inﬂuence the
development of C-ALD. The use of glyceryl trioleate-
trieurucate oil (Lorenzo’s oil) has been of interest as
a means of decreasing the levels of VLCFA and by so doing
potentially reducing the proportion of patients developing
the cerebral form of the disease. However, it is clear that
when C-ALD develops, Lorenzo’s oil does not modify the
course of the disease. In patients with C-ALD, inﬂammation
of the white matter of the brain is observed. Within these
regions there are changes suggestive of active oxidative
damage, thought to be related to cerebral inﬂammation [18].
Cerebral disease is progressive once it is initiated, generally
leading to a vegetative state or death within several years of
onset. The only currently available therapy for active C-ALD is
allogeneic hematopoietic stem cell transplantation (HSCT).
Aubourg et al. ﬁrst reported the beneﬁcial effect of HSCT ina boy with early-stage C-ALD in 1990 [19]. Themechanism by
which transplantation arrests the disease process remains
unknown. It is thought that the inﬂammatory response is
eliminated with the transplant, and this at least in part is
responsible for the alteration in the course of the disease. It is
possible that donor microglial cells play a role in supporting
the oligodendrocyte, and the early reported success of gene
therapy appears to support this [20]. After successful trans-
plantation, it is clear that progression of the disease can be
arrested, and this may persist for at least 5 to 10 years after
transplantation. At this time, transplantation is the standard
of care for boys with early-stage C-ALD.
Limitations of Transplantation for ALD
A number of patients with ALD are identiﬁed through
a positive family history or through non-neurologic symp-
tomatology such as an episode of adrenal crises that leads to
testing of VLCFA levels. For these patients close monitoring,
including periodic magnetic resonance imaging (MRI) eval-
uations, are undertaken to identify patients early in course of
the cerebral form of the disease. When MRI changes charac-
teristic of C-ALD are observed, patients are referred for allo-
geneic HSCT. Patients transplanted early in the course of
C-ALD, as deﬁned by an MRI severity score < 9 or 10, do well
with transplantation [21,22]. Unfortunately, many boys are
not diagnosed as having ALD until they develop neurologic
changes, including problemswith vision or hearing, difﬁculty
in school, or motor abnormalities. When these advanced
patients have undergone transplantation, the morbidity and
mortality ismuch higher. The Loes score, a 34-point systemof
ratingMRI changes in ALD, has been found to be predictive of
survival after HSCT [23,24]. Overall, the 5-year survival rate of
patients with a Loes score < 9 before transplantation was
reported as 92%, versus 45% in patients with a Loes score > 9
and more than one neurologic deﬁcit [22]. It is important to
point out that when boys with advanced disease undergo
transplantation, the toxicity associated with the procedure
itself commonly leads to signiﬁcant disease progression, and
the most common cause of death in patients with ALD is
progressive disease. Historically, in the advanced population,
although stabilization may be achieved after transplantation,
it may occur at a level of functioning much inferior to their
clinical status before initiating the transplant process.
Modiﬁcations in “Standard” Transplant Approaches for
Advanced C-ALD
Several large studies have documented very good
outcomes in patients with early C-ALD, as deﬁned by an MRI
severity score of <9 or <10 using a fully ablative regimen,
most commonly based on a busulfan/cyclophosphamide as
the primary agents. However, it also is clear that the pop-
ulation of advanced patients with C-ALD has done poorly
with this approach. Based on this, a new regimen was
developed using a reduced intensity preparative regimen
consisting of Campath (0.3 mg/kg  5 doses), clofarabine (40
mg/m2  5 doses), melphalan 140 mg/m2 and 200 cGy of
total body irradiation. In addition to this, due to concern
about oxidative damage contributing to disease progression
during the transplant process, N-acetylcysteine (NAC) was
added to the regimen. In a recent report of the transplant
experience with ALD at the University of Minnesota, the
5 year probability of survival for patients with a baseline Loes
score<10 was 89% (95% CI, 70%-96%), while for patients with
a Loes score 10 just prior to transplant was 60% (95% CI,
34%-78%; P ¼ 0.03). Within this group of high-risk patients,
Figure 1. Outcomes in Advanced C-ALD. In patients undergoing trans-
plantation for ALD with a MRI score of >10, survival is improved with
a reduced intensity (RI) regimen and N-acetylcysteine in comparison to a fully
ablative regimen.
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utilized. In comparing the outcomes of patients receiving this
reduced intensity transplant with NAC (n ¼ 16) to the
advanced group with a fully ablative regimen and no NAC,
a statistical difference in survival was observed (P ¼ 0.02)
(Figure 1).
Future Considerations; Transplantation for ALD
The ability to improve survival in advanced cases of ALD
through modiﬁcation of the conditioning regimen and
supportive care suggests that additional beneﬁts may be
realized by developing alternative, or additive, methodology
to provide “neuroprotection” for advanced patients under-
going transplantation. This would prove extremely impor-
tant in ALD, as in the majority of cases the diagnosis of
cerebral ALD is not established until neurologic changes are
recognized, and a high proportion of these cases have
advanced disease. In this population, the focus should be not
only to improve survival, but to minimize the neurocognitive
decline so often observed in these patients as they proceed
through transplant. This is now the limiting factor in
achieving acceptable outcomes. It is important to recognize
that is not known whether transplantation plays any role in
preventing the evolution of other manifestations of the ALD,
such as adrenomyeloneuropathy. In addition, there is to date
no means of identifying which patients with biochemically
proven ALD will develop cerebral disease. Therefore, the
risks of transplantation are not justiﬁed in patients without
evidence of evolving C-ALD. Based on these considerations it
is clear that early identiﬁcation of boys with ALD could save
lives, as well as minimize the development of life-long
disability in more advanced patients. Methodology for
newborn screening for ALD is actively being tested, and if
successful will provide a great opportunity for early diag-
nosis, which may change the landscape for cellular therapy
for ALD.
APPROACHES FOR OUTCOME ASSESSMENTS IN
HEMATOPOIETIC CELL THERAPY FOR METABOLIC
DISEASE: CHALLENGES FOR THE FUTURE
Gerald Raymond
Introduction
Since the ﬁrst successful transplants for nonhematologic
disorders in the early 1980s, a major question has been how
to measure disease-related outcomes in a meaningful way.
The ideal outcome assessment should be biologically valid,clinically relevant, and reproducible in all centers. It should
also be performed in the pretransplant assessment so that
the change over time is meaningful. Unfortunately, such an
ideal outcome assessment has yet to be realized. Although it
is clinically important to discuss the traditional “transplant-
related” parameters such as rates of engraftment, survival,
and complications such as graft-versus-host disease, for the
most part these outcomes give only the most superﬁcial of
information regarding disease outcome [22,25]. Similarly,
transplant outcomes are generally amenable to short-term
assessments, such as 2- or 5-year survival rates. In contrast,
in the case of X-linked ALD, determinations of the develop-
ment of myelopathy (adrenomyeloneuropathy) may require
a follow up period of 20 to 30 years [26].
It also needs to be emphasized thatmetabolic diseases are
not one disorder, and there is wide variation on organ
involvement. On this basis, assessment of outcomes is very
likely to be disease speciﬁc. For instance, monitoring
outcomes for HS is fundamentally different from those for
inherited leukodystrophies, and even within the leukodys-
trophies ALD is a peroxisomal disorder, whereas GLD and
MLD are lysosomal and are clinically and biologically distinct.
In addition, because there are varied phenotypes within
these diseases and transplantation may occur relatively early
or late within each phenotype, outcome analysis is even
more problematic. Despite all these issues, progress has been
made and is likely to become increasingly possible with new
methods to obtain insight directly of the disease state.Biochemical Markers
The measurement of biochemical metabolites in blood
and urine is essential in the diagnosis and well engrained in
the discussion of any form of treatment. What is often lack-
ing, however, is a good correlation between clinical measures
and biochemical abnormalities. This is partly due to failure to
measure abnormalities in the affected tissues themselves
because of the inability to access tissues such as bone, the
heart, and the central nervous system to measure the rele-
vance of biomarker studies. Therefore, the unclear relevance
of the use of biomarkers reﬂects our limited understanding
of the pathogenesis and the role of accumulated metabolites
and the limited use of them in assessing the natural history
of these disorders. For example, in ALD, evenwith successful
transplantation and disease arrest, the levels of VLCFAs, the
prominent biochemical abnormality, do not normalize.
However, with better understanding and technologies,
meaningful biochemical markers may be better explored and
their utility deﬁned. In animal models of HS, it has now
been established that HCT and intrathecal ERT can be
shown to decrease glycosaminoglycan levels associated with
improvement in affected tissues [27]. The ability to measure
glycosaminoglycan levels in a universal manner would be an
advancement in determining response to treatment. In
addition, there is emerging evidence that markers of
inﬂammation or extent of disease in ALD may affect prog-
nosis [28]. The challenges become developing relevant and
validated biochemical markers. Because in many disorders
we do not presently possess them, the creation of a bio-
repository for future study may prove of great use; this
would require extensive discussion regarding what should
be stored: blood, urine, cerebrospinal ﬂuid, other tissues? In
addition, it will be important to address the costs for this
repository, as well as mechanisms for storage and access.
P. Orchard et al. / Biol Blood Marrow Transplant 19 (2013) S58eS63S62Clinical Outcomes
Clinical measures will vary with the disease but should be
designed for pre- and post-treatment assessments thatwill be
comparable. Because the metabolic disorders that undergo
HCT are progressive, the scales should assess the full range of
disease over time. The ideal clinical rating scales are simple,
sensitive, and clinically relevant. Intra- and inter-rater varia-
tion should be established. They should not require special
equipment or expertise. Although seeming to lack in sophis-
tication, these measures are in reality the most important
outcome assessors. The ability to state what the functional
level may be after HCT is information that patients and their
familiesmostwant toknow.Theyalsoallowmultiplecenters to
pool datawith a minimum of investment. For instance, in ALD
several scales have been developed, including the Neurologic
Functional Scale [29],ALDdisability rating scale [22],AdultALD
Disability Score, and a modiﬁed Rankin score [30]. Although
differing in certain aspects, each of these scoring systems
focuses on the key neurologic aspects of progressive ALD, and
so the only major limitation in making a multicenter compar-
ison is lack of a consensus onwhich to be used.
In discussing clinical outcome assessments, one can
examine neuropsychological testing. The testing of intelli-
gence, language, attention, memory, and academic perfor-
mance is an important consideration in the evaluation of any
therapy. These aspects are not well covered on a standard
neurologic exam. Neuropsychological testing requires time
and trained personnel. It is absolutely essential that a deter-
mination of what testing will be carried out is established
before a multi-institutional study. Experience has demon-
strated that testing is best performed by centers that routinely
assess affected individuals. Other considerations complicating
these endpoints include language and cultural constraints.
Although essential for the assessment of neurologic develop-
ment, performance on neuropsychological testing is highly
susceptible to other confounders, including medication,
intercurrent illness, motivation, and neuropsychiatric state
(depression). Unfortunately, in the cases of signiﬁcant
acquired impairment (eg, blindness ordeafness), theremaybe
inability to perform entire areas of testing.
Imaging
Most of the present metabolic disorders for which HCT is
performed have neurologic involvement, but this is not
universal. However, the ability to image the brain and spinal
cord has had a profound effect on our ability to deﬁne disease,
andmanyof the techniques involved carryover toother tissues.
The ability to image other organs, including the heart, lungs,
bones, and liver, for disease burden is changing our ability to
track disease before and after treatment. In the leukodystro-
phies, there is involvement of myelin and imaging changes on
conventionalMRI. Hyperintensities are seen on speciﬁc images
and can be tabulated. These have allowed development of
rating scales that essentially count areas of involvement. An
example is the ALD MRI (Loes) score that has been well vali-
dated and has shown robust inter-rater validity [24,31].
Beyond conventional imaging, developing techniques
include the use of different sequences that allows one to
examine the structure and properties of myelin and axons.
These techniques include diffusion tensor imaging, magne-
tization weighted imaging, and magnetic resonance spec-
troscopy and not only allow qualitative images but provide
quantitative metrics that may be tracked over time. The
multiple issues with the widespread adaptation of these
newer technologies include standardization of sequenceacquisition, recognition of artifacts, timing of pre- and post-
treatment scanning, and the requirement of postprocessing,
which requires time and expertise.
Issues with Multicenter Investigations
Becausemanyof thesedisorders are very rare, fewpatients
will generally come to attention and treatment in a particular
center. This begs the question as to whether transplants for
metabolic disorders should be performed primarily at centers
with demonstrated expertise in the condition. Although one
could argue that thismaybe optimal and could lead to greater
uniformity in the pre- and post-transplant evaluations, it
unfortunately does not reﬂect the reality of present medical
care.What then is an adequate compromise? The answermay
be consortiums of treating institutions with agreement on
minimum standards of outcome assessments.
Within these consortiums consideration should be given
to centralized data storage so that available information can
be maintained and studied. This naturally requires space,
human resources, and a funding commitment that supports
it for a reasonable period of time. A number of questions
naturally follow, such as what information should be stored
and should it include imaging data. For the leukodystrophies
such as ALD MRI data are important [25,32], and for MPS
diseases such as HS x-rays of knees, hips, and so on are useful
as well. Additionally, would this database include raw and
scored neuropsychological information? Does it provide for
access to samples? Because samples will be limited, what
method will be used to judge the quality and risk? Will the
subjects have the right to request retrieval of their samples?
These are all difﬁcult questions, but clearly they could be
agreed on if funding were provided.
There should also be the ability to offer patients and their
family participation in other studies, either in association
with or as an alternative to transplantation. Overcoming
restrictions of institutional review boards and other legal
issues will remain a challenge. Knowing the patient pop-
ulation available would certainly allow more focused grant
applications, and one could foresee potentially performing
promising new imaging methods at only a few selected
centers. Although the issues appear to be a signiﬁcant hurdle,
if we wish to continue to improve the care provided to these
children and adults, we need to provide better answers on
outcomes in both the short and long term. This will
increasingly become critical when questions are asked of an
expensive therapy for rare disorders.
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